Cargando…

Prognostic Value of (18)F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

BACKGROUND AND AIM: The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quaquarini, E., D'Ambrosio, D., Sottotetti, F., Gallivanone, F., Hodolic, M., Baiardi, P., Palumbo, R., Vellani, C., Canevari, C., Bernardo, A., Castiglioni, I., Porta, C., Trifirò, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458948/ https://www.ncbi.nlm.nih.gov/pubmed/31049043 http://dx.doi.org/10.1155/2019/4325946

Ejemplares similares

Parameters Influencing PET Imaging Features: A Phantom Study with Irregular and Heterogeneous Synthetic Lesions
por: Gallivanone, Francesca, et al.
Publicado: (2018)

A Partial Volume Effect Correction Tailored for (18)F-FDG-PET Oncological Studies
por: Gallivanone, F., et al.
Publicado: (2013)

A Method for Manufacturing Oncological Phantoms for the Quantification of 18F-FDG PET and DW-MRI Studies
por: Gallivanone, Francesca, et al.
Publicado: (2017)

Fluorocholine PET Imaging of Parathyroid Disease
por: Prabhu, Meghana, et al.
Publicado: (2018)

Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone
por: De Giorgi, Ugo, et al.
Publicado: (2014)

Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer
por: Hodolic, Marina, et al.
Publicado: (2014)

Biomarkers from in vivo molecular imaging of breast cancer: pretreatment (18)F-FDG PET predicts patient prognosis, and pretreatment DWI-MR predicts response to neoadjuvant chemotherapy
por: Gallivanone, Francesca, et al.
Publicado: (2017)

Incidental Findings on (18) F-Fluorocholine PET/CT for Parathyroid Imaging
por: Broos, Wouter A.M., et al.
Publicado: (2022)

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer
por: Conteduca, V., et al.
Publicado: (2017)

Preoperative Imaging with [(18)F]-Fluorocholine PET/CT in Primary Hyperparathyroidism
por: Dekorsy, Franziska J., et al.
Publicado: (2022)

Intra-vagal parathyroid adenoma on digital PET/CT with (18)F-fluorocholine
por: Mainta, Ismini C., et al.
Publicado: (2021)

Detection of Synchronous Parathyroid Adenoma and Breast Cancer with (18)F-Fluorocholine PET-CT
por: Vorselaars, Wessel MCM, et al.
Publicado: (2015)

Palbociclib in metastatic breast cancer: current evidence and real-life data
por: Serra, Francesco, et al.
Publicado: (2019)

Detection of an undescended parathyroid adenoma with (18)F-fluorocholine PET/CT
por: Booij, J., et al.
Publicado: (2022)

Chronic Liver Disease and the Detection of Hepatocellular Carcinoma by [(18)F]fluorocholine PET/CT
por: Kwee, Sandi A., et al.
Publicado: (2015)

Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CT
por: Rep, Sebastijan, et al.
Publicado: (2015)

Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer
por: Kim, Jung Kwon, et al.
Publicado: (2022)

Fluorine-18-fluorocholine PET/CT parameters predictive for hematological toxicity to radium-223 therapy in castrate-resistant prostate cancer patients with bone metastases: a pilot study
por: Vija Racaru, Lavinia, et al.
Publicado: (2018)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Differentiation of hepatocellular adenoma and focal nodular hyperplasia using (18)F-fluorocholine PET/CT
por: van den Esschert, Jacomina W., et al.
Publicado: (2010)

(18)F-Fluorocholine PET and 4D-CT in Patients with Persistent and Recurrent Primary Hyperparathyroidism
por: Latge, Adrien, et al.
Publicado: (2021)

Quantification of internal dosimetry in PET patients II: Individualized Monte Carlo‐based dosimetry for [18F]fluorocholine PET
por: Neira, Sara, et al.
Publicado: (2021)

Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
por: Palumbo, Raffaella, et al.
Publicado: (2019)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US
por: Arteaga-Marrero, Natalia, et al.
Publicado: (2015)

Feasibility of (18)F-Fluorocholine PET for Evaluating Skeletal Muscle Atrophy in a Starved Rat Model
por: Park, Sun Mi, et al.
Publicado: (2022)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Erratum to: Radiation treatment monitoring using multimodal functional imaging: PET/CT ((18)F-Fluoromisonidazole & (18)F-Fluorocholine) and DCE-US
por: Arteaga-Marrero, Natalia, et al.
Publicado: (2016)

(18)F-Fluorocholine PET and Multiphase CT Integrated in Dual Modality PET/4D-CT for Preoperative Evaluation of Primary Hyperparathyroidism
por: Pretet, Valentin, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Role of androgen receptor expression in early stage ER+/PgR−/HER2– breast cancer
por: Tagliaferri, Barbara, et al.
Publicado: (2020)

Role of (18)F-choline PET/CT in evaluation of patients with prostate carcinoma
por: Hodolic, Marina
Publicado: (2010)

Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging
por: Kwee, Sandi A., et al.
Publicado: (2012)

Visualization of Macroprolactinoma by (18)F-Fluorocholine PET/CT in a Patient With Multiple Endocrine Neoplasia Type 1
por: Paepegaey, Anne-Cécile, et al.
Publicado: (2018)

[(18)F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancer
por: Pasqualetti, Francesco, et al.
Publicado: (2019)

Value of 18F-fluorocholine PET/CT in predicting response to radical radiotherapy in patients with localized prostate cancer
por: Sepulcri, Matteo, et al.
Publicado: (2021)

Hyperfunctioning parathyroid gland and skeletal involvement on [(18)F]fluorocholine PET/CT: one look with two views
por: Nappi, Carmela, et al.
Publicado: (2022)

Detection of recurrence sites using (18)F-fluorocholine PET/CT in prostate cancer patients with PSA failure
por: Kim, Dong-Yun, et al.
Publicado: (2023)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Troubleshooting for F-18 Fluorocholine Synthesis: An Institutional Experience
por: Vatsa, Rakhee, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b45pmoce7vc2aeha623kitfi5g